Novogen Ltd., of Sydney, has acquired Glioblast Pty Ltd., a privately held, neuro-oncology-focused Australian biotechnology company, to support development of GDC-0084, a small-molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway newly licensed from Basel, Switzerland-based Roche AG's Genentech Inc.